Fairmont Hotel Vancouver Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2007



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Tuberculosis: From Lab Research to Field Trials (C6)


Organizer(s) Stefan H.E. Kaufmann, Issar Smith and Carl F. Nathan
March 20—25, 2007
Fairmont Hotel Vancouver • Vancouver, British Columbia Canada
Abstract Deadline: Nov 20, 2006
Late Abstract Deadline: Dec 20, 2006
Scholarship Deadline: Nov 20, 2006
Early Registration Deadline: Jan 22, 2007

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation

Summary of Meeting:
Tuberculosis remains one of the major infectious disease killers in the world. This is in spite of the fact that, in most cases, the host response is capable of controlling Mycobacterium tuberculosis infection efficiently: only a minority of infected individuals develops active tuberculosis. The situation is exacerbated by increasing incidences of multi-drug-resistant strains and the dangerous liaison between tuberculosis and AIDS. Recent accomplishments in molecular genetics, cell biology, structural biology and immunology have provided the clues to an in-depth understanding of the crosstalk between pathogen and host which leads to latency, resuscitation, disease outbreak, susceptibility and protective immunity. Application of state-of-the-art technologies will help in elucidating underlying molecular mechanisms and in identifying the responsible gene products both on the side of the invader and its host. Based on such insights, novel vaccination strategies can be pursued and new drug candidates developed. This meeting will discuss the most recent findings in the broad field of research activities relevant to a better understanding of tuberculosis and provide a forum for intensive discussions and collaborations for scientists ranging from basic research to field studies. The meeting, therefore, will also promote exchange between and amalgamation of highly sophisticated research approaches and fundamental issues of disease control.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


TUESDAY, MARCH 20

15:00—19:30
Registration

BC Foyer
18:30—19:30
Refreshments

Pacific Ballroom
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

British Columbia Ballroom
Gerald H. Friedland, Yale University, USA
Extensively Drug Resistant TB (XDR-TB) in Rural South Africa - Tip of the Iceberg?


WEDNESDAY, MARCH 21

07:00—08:00
Breakfast

Saturna/ Vancouver Island/ Pacific Ballroom
08:00—11:00
Bacterial Metabolism and Biochemistry
Meeting has ended...abstracts no longer viewable online.

British Columbia Ballroom
Carl F. Nathan, Weill Cornell Medical College, USA
Selective Killing of Non-Replicating Mycobacteria by Inhibitors of Dihydrolipoamide Acyl Transferase

Mamadou Daffé, Centre National de la Recherche Scientifique, France
Biosynthesis and Function of Mycobacteria Cell Wall Components

* Rajesh S. Gokhale, National Institute of Immunology, India
Versatile Polyketide Enzymatic Machinery for Biosynthesis of Complex Mycobacterial Lipids

David R. Sherman, Seattle Biomedical Research Institute, USA
Environmental Sensing and TB Metabolism

Carlos Martin, University of Zaragoza, Spain
Short Talk: Live Vaccines Based on phoP Mutants: A Step Toward Clinical Trials

09:20—09:40
Coffee Break

BC Foyer
11:00—13:00
Poster Setup

Pacific Ballroom
13:00—22:00
Poster Viewing

Pacific Ballroom
14:30—16:30
Workshop 1: Drugs against Tuberculosis

British Columbia Ballroom
* Ann M. Ginsberg, Aeras, USA
Recent Advances in TB Drug Development

Barrington J. A. Furr, AstraZeneca, UK
Validated Targets and Antituberculosis Drug Discovery

Vasan Sambandamurthy, Novartis Institute for Tropical Diseases, Singapore
A Chemical Genetics Approach to Identify Essential Targets in Mycobacterium tuberculosis

Jacques H. Grosset, Johns Hopkins School of Medicine, USA
Current Problems and Possible Solutions for the Chemotherapy of Tuberculosis

Douglas B. Young, Imperial College London, UK
Drugs for Treatment of Latent TB: a Grand Challenge in Global Health

16:30—17:00
Coffee Available

BC Foyer
17:00—19:00
Latency and Novel Intervention Strategies
Meeting has ended...abstracts no longer viewable online.

British Columbia Ballroom
Helena I. M. Boshoff, NIAID, National Institutes of Health, USA
Metabolism in Latent Tuberculosis

Eric J. Rubin, Harvard School of Public Health, USA
Requirements for Mycobacterial Growth in vitro and in vivo

Nicole Kruh-Garcia, Colorado State University, USA
Short Talk: A Novel Interaction Between the FAS-II and PDIM Biosynthetic Pathways

William R. Bishai, Johns Hopkins School of Medicine and K-RITH, USA
Modeling TB Pathogenesis: Have We Been Mouse Led?

19:00—20:00
Social Hour with Lite Bites

Pacific Ballroom
19:30—22:00
Poster Session 1

Pacific Ballroom

THURSDAY, MARCH 22

07:00—08:00
Breakfast

Saturna/ Vancouver Island/ Pacific Ballroom
08:00—11:00
Functional and Structural Analysis on a Global Level
Meeting has ended...abstracts no longer viewable online.

British Columbia Ballroom
Issar Smith, Public Health Research Institute/ICPH, USA
Global Response of M. tuberculosis to the Environment

* William R. Jacobs, Jr., HHMI/Albert Einstein College of Medicine, USA
Eradicating Tuberculosis, A War on Two Fronts: Chemotherapy and Immune Evasion Mechanisms

Lindsay D. Eltis, University of British Columbia, Canada
Short Talk: Characterization of Cholesterol-Degrading Enzymes Critical for the Survival of Mycobacterium Tuberculosis in the Macrophage

Brian D. Robertson, Imperial College London, UK
Look Global, Focus Local

Matthias Wilmanns, European Molecular Biology Laboratory Hamburg, Germany
Towards the Proteome of Mycobacterium Tuberculosis in 3D

09:20—09:40
Coffee Break

BC Foyer
11:00—13:00
Poster Setup

Pacific Ballroom
13:00—22:00
Poster Viewing

Pacific Ballroom
14:30—16:30
Workhop 2: Oral Abstract Presentations

British Columbia Ballroom
* Camille Locht, Institut Pasteur de Lille, France
From Extrapulmonary Dissemination to Diagnosis of Latent M. tuberculosis Infection and Novel Vaccine Development

Marc Jacobsen, University Hospital Duesseldorf, Germany
Clonal Expansion of CD8+ Effector T Cells in Childhood Tuberculosis

J. Muse Davis, University of Washington, USA
Mechanisms of Mycobacterial Dissemination Within and From Early Tuberculous Granulomas Revealed by Long-Term Live Imaging of Mycobacterium Marinum-Infected Zebrafish Embryos

Anthony J. Hickey, University of North Carolina at Chapel Hill, USA
Needle-Free Vaccination by BCG-LPP Aerosols in the Guinea Pig

Kari Ann Sweeney, Albert Einstein College of Medicine, USA
A M. Tuberculosis Gene Cluster that Prevents IL-12 Induction and Innate Immune Killing

Jeff E. Grotzke, Oregon Health & Science University, USA
The Mycobacterium Tuberculosis Phagosome: Evidence for ER-derived HLA-I Antigen Processing and Presentation

Sandhya S. Visweswariah, Indian Institute of Science, India
Cyclic AMP and Mycobacteria: Roles of Nucleotide Cyclases and Phosphodiesterases

16:30—17:00
Coffee Available

BC Foyer
17:00—19:00
Cell and Tissue Response
Meeting has ended...abstracts no longer viewable online.

British Columbia Ballroom
Sabine Ehrt, Weill Cornell Medical College, USA
Host Defense and Mycobacterial Virulence

* Alan Sher, NIAID, National Institutes of Health, USA
Cellular Dynamics of Granuloma Formation and Maintenance Revealed by Intravital Imaging

Hardy Kornfeld, University of Massachusetts Medical School, USA
Short Talk: Multiple Death Modes of M. tuberculosis-Infected Macrophages

John D. MacMicking, Yale University, USA
Immunity-Related GTPases (IRGs) in Host Defense against Tuberculosis

19:00—20:00
Social Hour with Lite Bites

Pacific Ballroom
19:30—22:00
Poster Session 2

Pacific Ballroom

FRIDAY, MARCH 23

07:00—08:00
Breakfast

Saturna/ Vancouver Island/ Pacific Ballroom
08:00—11:00
Genetic Determinants of Disease (Host and Pathogen)
Meeting has ended...abstracts no longer viewable online.

British Columbia Ballroom
* Peter M. Small, Bill & Melinda Gates Foundation, USA

Igor B. Kramnik, Boston University, USA
Experimental Mouse Model of Pulmonary Tuberculosis: Genetic Perspectives

Laurent Abel, INSERM U550, Necker Medical School, France
Human Genetics of Tuberculosis: A Continuous Spectrum of Predisposition

Pedro O. Flores-Villanueva, Methodist Hospital Research Institute, USA
MCP-1 Gene, Host Determinant of Progression from Infection to Disease

Diane Houben, Netherlands Cancer Institute, Netherlands
Short Talk: M. tuberculosis and M. leprae Translocate From the Phagolysosome to the Cytosol in Myeloid Cells

Sébastien Gagneux, Swiss Tropical and Public Health Institute, Switzerland
Evolution of Mycobacterium tuberculosis

09:20—09:40
Coffee Break

BC Foyer
11:00—13:00
Poster Setup

Pacific Ballroom
13:00—22:00
Poster Viewing

Pacific Ballroom
14:30—16:30
Workshop 3: Vaccines against Tuberculosis

British Columbia Ballroom
Uli Fruth, World Health Organization, Switzerland
What is Role of the World Health Organization in TB Vaccine Development?

* Christine F. Sizemore, NIAID, National Institutes of Health, USA
NIAID's Extramural TB Program - Contributions to TB Science and Vaccine Development

Alexander von Gabain, Valneva SE, France
Characterization of IC31TM, a Novel Multipurpose Adjuvant with a Profile Matching the Need of TB Vaccines

Pascal Mettens, GlaxoSmithKline, Belgium
Prospects For Tuberculosis Vaccine Based On The Mtb72F/AS02A

Francois Spertini, Centre Hospitalier Universitaire Vaudois, Switzerland
Safety and Immunogenicity of the Mtb72F/AS02A Tuberculosis Vaccine in PPD-Positive Swiss Adults

Albrecht Läufer, Corvay GmbH, Germany
Developing a TB Vaccine for Human Use

Jerald C. Sadoff, Crucell Vaccine Institute, Janssen Pharmaceutical Companies of Johnson & Johnson, Netherlands
Aeras TB Vaccine Development

16:30—17:00
Coffee Available

BC Foyer
17:00—19:30
Immune Response and Correlates of Protection
Meeting has ended...abstracts no longer viewable online.

British Columbia Ballroom
* Gilla Kaplan, Bill & Melinda Gates Foundation, USA
Immunologic Correlates of Protective Immunity against TB in BCG-Vaccinated Neonates

Anne E. Goldfeld, Children's Hospital Boston, Harvard Medical School, USA
Human Inflammatory Response Against M. tuberculosis

Tom H. M. Ottenhoff, Leiden University Medical Center, Netherlands
Immunoregulation and Suppression in Human Tuberculosis

David M. Lewinsohn, Oregon Health & Science University, USA
Short Talk: Defining Immunodominance in the Human CD8+ T Cell Response to Mtb

Larry S. Schlesinger, Texas Biomedical Research Institute, USA
Regulation of Lung Inflammation by Macrophages: Impact of the Alveolar Microenvironment on Tuberculosis Pathogenesis

19:00—20:00
Social Hour with Lite Bites

Pacific Ballroom
19:30—22:00
Poster Session 3

Pacific Ballroom

SATURDAY, MARCH 24

07:00—08:00
Breakfast

Saturna/ Vancouver Island/ Pacific Ballroom
08:00—11:00
Vaccines
Meeting has ended...abstracts no longer viewable online.
World TB Day. 125 Years after the Discovery of the Etiology of Tuberculosis

British Columbia Ballroom
Stefan H. E. Kaufmann, Max Planck Institute for Infection Biology, Berlin, Germany
Recombinant BCG with Improved Immunogenicity

Peter Andersen, Statens Serum Institut, Denmark
Subunit Vaccines Against Tuberculosis

* Marcus A. Horwitz, University of California, Los Angeles, USA
New More Potent and Safer Recombinant BCG Vaccines Against Tuberculosis

Helen McShane, Jenner Institute, UK
Boosting BCG with MVA85A - Results from Clinical Trials

09:20—09:40
Coffee Break

BC Foyer
11:00—12:00
Poster Setup

Pacific Ballroom
12:00—13:00
Lunch

Pacific Ballroom/ Saturna/ Vancouver Island
13:00—17:00
Poster Session 4

Pacific Ballroom/ Saturna/ Vancouver Island
16:30—17:00
Coffee Available

BC Foyer
17:00—19:00
Beyond the Wet Lab - Clinical Experience and Trials
Meeting has ended...abstracts no longer viewable online.

British Columbia Ballroom
Michael Levin, Imperial College London, UK
Insights into the Immunological Basis of Susceptibility and Resistance to Mycobacteria from Studies on Patients

* Neil W. Schluger, Columbia University College of Physicians and Surgeons, USA
Tuberculosis Clinical Trials: Past, Present and Future

Greg D. Hussey, University of Cape Town, South Africa
Development of a Tuberculosis Vaccine Trial Site in South Africa: Challenges and Lessons Learned

19:00—20:00
Social Hour with Lite Bites

Pacific Ballroom
20:00—23:00
Entertainment

Pacific Ballroom

SUNDAY, MARCH 25

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 U13 AI60000-01




National Institutes of Health

Grant No. 1R13AI072803-01




We gratefully acknowledge additional support for this conference from:

Bill & Melinda Gates Foundation Burroughs Wellcome Fund
GlaxoSmithKline UK Intercell AG
Novartis Pharma AG
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



GlaxoSmithKline


Intercell AG


Novartis Institute for Tropical Diseases Pte Ltd


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676